IHH Healthcare Berhad Just Missed EPS By 8.6%: Here’s What Analysts Think Will Happen Next

As you might know, IHH Healthcare Berhad (KLSE:IHH) last week released its latest quarterly, and things did not turn out so great for shareholders. IHH Healthcare Berhad missed analyst forecasts, with revenues of RM6.6b and statutory earnings per share (EPS) of RM0.06, falling short by 6.5% and 8.6% respectively. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from IHH Healthcare Berhad’s 23 analysts is for revenues of RM28.2b in 2026. This would reflect a solid 8.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to accumulate 9.1% to RM0.26. In the lead-up to this report, the analysts had been modelling revenues of RM28.3b and earnings per share (EPS) of RM0.26 in 2026. So it’s pretty clear that, although the analysts have updated their estimates, there’s been no major change in expectations for the business following the latest results.

View our latest analysis for IHH Healthcare Berhad

It will come as no surprise then, to learn that the consensus price target is largely unchanged at RM10.13. There’s another way to think about price targets though, and that’s to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on IHH Healthcare Berhad, with the most bullish analyst valuing it at RM11.43 and the most bearish at RM8.50 per share. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the IHH Healthcare Berhad’s past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of IHH Healthcare Berhad’shistorical trends, as the 11% annualised revenue growth to the end of 2026 is roughly in line with the 12% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 10% annually. So although IHH Healthcare Berhad is expected to maintain its revenue growth rate, it’s only growing at about the rate of the wider industry.

The Bottom Line

The most important thing to take away is that there’s been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company’s earnings is a lot more important than next year. We have estimates – from multiple IHH Healthcare Berhad analysts – going out to 2028, and you can see them free on our platform here.

That said, it’s still necessary to consider the ever-present spectre of investment risk. We’ve identified 1 warning sign with IHH Healthcare Berhad , and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.